High response was significantly associated with clinical stage (<i>p</i> = 0.034), tumor grade (<i>p</i> < 0.001), HER2 status (<i>p</i> < 0.001), ER status (<i>p</i> < 0.001), PR status (<i>p</i> < 0.001), and Ki-67 levels (<i>p</i> < 0.001). This evidence concerns the gene ERBB2 and neoplasm.